Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer, January 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 221 articles:
HTML format


 

Single Articles

  1. LI Z, Sun M, Wang F, Shi J, et al
    Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis.
    Int J Clin Pharmacol Ther. 2016 Dec 27. doi: 10.5414/CP202670.
    Abstract    

    Abstract available

  2. ALI ZIRAKZADEH A, Kinn J, Krantz D, Rosenblatt R, et al
    Doxorubicin enhances the capacity of B cells to activate T cells in Urothelial Urinary Bladder Cancer.
    Clin Immunol. 2016 Dec 23. pii: S1521-6616(16)30197.
    Abstract    

    Abstract available

  3. HINSCH A, Chaker A, Burdelski C, Koop C, et al
    betaIII-tubulin overexpression is linked to agressive tumor features and genetic instability in urinary bladder cancer.
    Hum Pathol. 2016 Dec 23. pii: S0046-8177(16)30351.
    Abstract    

    Abstract available

  4. PAGLIARULO V, Ancona P, Petitti T, Salerno A, et al
    Detection and Clinical Significance of Circulating Tumor Cells in Patients Undergoing Radical Cystectomy for Urothelial Bladder Cancer.
    Clin Genitourin Cancer. 2016 Dec 1. pii: S1558-7673(16)30341.
    Abstract    

    Abstract available

  5. RAOULT D
    Is there a link between urinary microbiota and bladder cancer?
    Eur J Epidemiol. 2016 Dec 24. doi: 10.1007/s10654-016-0213.
    Abstract    



  6. SUN X, Deng Q, Liang Z, Liu Z, et al
    Cigarette smoke extract induces epithelial-mesenchymal transition of human bladder cancer T24 cells through activation of ERK1/2 pathway.
    Biomed Pharmacother. 2016;86:457-465.
    Abstract    

    Abstract available

  7. GOGALIC S, Sauer U, Doppler S, Heinzel A, et al
    Validation of a protein panel for the non-invasive detection of recurrent non-muscle invasive bladder cancer.
    Biomarkers. 2016 Dec 23:1-27. doi: 10.1080/1354750X.2016.1276628.
    Abstract    

    Abstract available

  8. POLOM W, Markuszewski M, Cytawa W, Czapiewski P, et al
    Fluorescent Versus Radioguided Lymph Node Mapping in Bladder Cancer.
    Clin Genitourin Cancer. 2016 Nov 30. pii: S1558-7673(16)30343.
    Abstract    

    Abstract available

  9. LISS MA, White M, Natarajan L, Parsons JK, et al
    Exercise Decreases and Smoking Increases Bladder Cancer Mortality.
    Clin Genitourin Cancer. 2016 Dec 1. pii: S1558-7673(16)30342.
    Abstract    

    Abstract available

  10. PICHLER R, Gruenbacher G, Culig Z, Brunner A, et al
    Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer.
    Cancer Immunol Immunother. 2016 Dec 22. doi: 10.1007/s00262-016-1945.
    Abstract    

    Abstract available

  11. TACHIBANA H, Gi M, Kato M, Yamano S, et al
    Carbonic anhydrase 2 is a novel invasion-associated factor in urinary bladder cancers.
    Cancer Sci. 2016 Dec 22. doi: 10.1111/cas.13143.
    Abstract    

    Abstract available

  12. BAI Y, Yang H, Zhang G, Hu L, et al
    Inhibitory effects of resveratrol on the adhesion, migration and invasion of human bladder cancer cells.
    Mol Med Rep. 2016 Dec 15. doi: 10.3892/mmr.2016.6051.
    Abstract    

    Abstract available

  13. CHENG S, Andrew AS, Andrews PC, Moore JH, et al
    Complex systems analysis of bladder cancer susceptibility reveals a role for decarboxylase activity in two genome-wide association studies.
    BioData Min. 2016;9:40.
    Abstract    

    Abstract available

  14. LIU D, Li Y, Luo G, Xiao X, et al
    LncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2.
    Cancer Lett. 2016 Dec 18. pii: S0304-3835(16)30750.
    Abstract    

    Abstract available

  15. ZARIFMAHMOUDI L, Sadeghi R
    Re: Radio-Guided Lymph Node Mapping in Bladder Cancer Using SPECT/CT and Intraoperative gamma-Probe Methods.
    Clin Nucl Med. 2016 Dec 16. doi: 10.1097/RLU.0000000000001485.
    Abstract    



  16. SAMY MD, Tong WL, Yavorski JM, Sexton WJ, et al
    T cell receptor gene recombinations in human tumor specimen exome files: detection of T cell receptor-beta VDJ recombinations associates with a favorable oncologic outcome for bladder cancer.
    Cancer Immunol Immunother. 2016.
    Abstract    

    Abstract available

  17. TRETTER EM, Ebel JJ, Pohar KS, Zynger DL, et al
    Does the gross prosector impact pT3 subclassification or lymph node counts in bladder cancer?
    Hum Pathol. 2016 Dec 16. pii: S0046-8177(16)30347.
    Abstract    

    Abstract available

  18. ZHANG XJ, Yu HY, Cai YJ, Ke M, et al
    Lycium barbarum polysaccharides inhibit proliferation and migration of bladder cancer cell lines BIU87 by suppressing Pi3K/AKT pathway.
    Oncotarget. 2016 Dec 15. doi: 10.18632/oncotarget.13963.
    Abstract    

    Abstract available

  19. WANG X, Ni S, Chen Q, Ma L, et al
    Bladder cancer cells induce immunosuppression of T cells by supporting PD-L1 expression in tumor macrophages partially through interleukin 10.
    Cell Biol Int. 2016 Dec 17. doi: 10.1002/cbin.10716.
    Abstract    

    Abstract available

  20. ROPERTO S, Munday JS, Corrado F, Goria M, et al
    Detection of bovine papillomavirus type 14 DNA sequences in urinary bladder tumors in cattle.
    Vet Microbiol. 2016;190:1-4.
    Abstract    

    Abstract available

  21. HARGRAVE C, Mason N, Guidi R, Miller JA, et al
    Automated replication of cone beam CT-guided treatments in the Pinnacle(3) treatment planning system for adaptive radiotherapy.
    J Med Radiat Sci. 2016;63:48-58.
    Abstract    

    Abstract available

  22. TAKAYAMA T, Kubo T, Morikawa A, Morita T, et al
    Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer.
    Med Oncol. 2016;33:45.
    Abstract    

    Abstract available

  23. MIKAMO H
    [Deep-seated mycosis].
    Med Mycol J. 2016;57:J33-4.
    Abstract    



  24. CHEN L, Li H, Gu L, Ma X, et al
    Prognostic role of urinary collecting system invasion in renal cell carcinoma: a systematic review and meta-analysis.
    Sci Rep. 2016;6:21325.
    Abstract    

    Abstract available

  25. TAN WS, Lamb BW, Kelly JD
    Evolution of the neobladder: A critical review of open and intracorporeal neobladder reconstruction techniques.
    Scand J Urol. 2016;50:95-103.
    Abstract    

    Abstract available

  26. RUIZ-TAMAYO I, Franch-Nadal J, Mata-Cases M, Mauricio D, et al
    Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications?
    J Diabetes Res. 2016;2016:7502489.
    Abstract    

    Abstract available

  27. LI XD, Chen SL, Dong P, Chen JW, et al
    Overexpression of RNF2 Is an Independent Predictor of Outcome in Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy.
    Sci Rep. 2016;6:20894.
    Abstract    

    Abstract available

  28. JIANG T, Liu T, Li L, Yang Z, et al
    Knockout of phospholipase Cepsilon attenuates N-butyl-N-(4-hydroxybutyl) nitrosamine-induced bladder tumorigenesis.
    Mol Med Rep. 2016;13:2039-45.
    Abstract    

    Abstract available

  29. ZHANG Z, Zhang G, Kong C, Zhan B, et al
    METTL13 is downregulated in bladder carcinoma and suppresses cell proliferation, migration and invasion.
    Sci Rep. 2016;6:19261.
    Abstract    

    Abstract available

  30. MONTIRONI R, Santoni M, Cheng L, Lopez-Beltran A, et al
    An Overview of Emerging Immunotargets of Genitourinary Tumors.
    Curr Drug Targets. 2016;17:750-6.
    Abstract    

    Abstract available

  31. ROUANNE M, Loriot Y, Lebret T, Soria JC, et al
    Novel therapeutic targets in advanced urothelial carcinoma.
    Crit Rev Oncol Hematol. 2016;98:106-15.
    Abstract    

    Abstract available

  32. BAACK KUKREJA JE, Messing EM, Shah JB
    Are we doing "better"? The discrepancy between perception and practice of enhanced recovery after cystectomy principles among urologic oncologists.
    Urol Oncol. 2016;34:120.
    Abstract    

    Abstract available

  33. PARISER JJ, Anderson BB, Pearce SM, Han Z, et al
    The effect of broader, directed antimicrobial prophylaxis including fungal coverage on perioperative infectious complications after radical cystectomy.
    Urol Oncol. 2016;34:121.
    Abstract    

    Abstract available

  34. HOLM PS, Retz M, Gschwend JE, Nawroth R, et al
    [YB-1-based virotherapy: A new therapeutic intervention for transitional cell carcinoma of the bladder?].
    Urologe A. 2016;55:356-63.
    Abstract    

    Abstract available

  35. HIRNER L, Stagge E, Rubben H, Schenck M, et al
    [Narrow band imaging-assisted cystoscopy in bladder tumor follow-up: Can more tumors be identified?].
    Urologe A. 2016;55:370-5.
    Abstract    

    Abstract available

  36. WANG YL, Fang N, Zeng L, Wu ZJ, et al
    18F-FDG PET/CT Findings of Metastasis to Spongy Body of Penis From Urothelial Carcinoma of Bladder.
    Clin Nucl Med. 2015.
    Abstract    

    Abstract available

  37. COLLINS JW, Adding C, Hosseini A, Nyberg T, et al
    Introducing an enhanced recovery programme to an established totally intracorporeal robot-assisted radical cystectomy service.
    Scand J Urol. 2016;50:39-46.
    Abstract    

    Abstract available

  38. LIU SL, Qi L, Han WQ, Zhu BS, et al
    Shorter hemodialysis duration is a risk factor for the recurrence of urothelial carcinoma of the bladder in patients on maintenance hemodialysis.
    Clin Transl Oncol. 2016;18:304-9.
    Abstract    

    Abstract available

  39. WANG CT, Chen TM, Mei CT, Chang CF, et al
    The Functional Haplotypes of CHRM3 Modulate mRNA Expression and Associate with Bladder Cancer among a Chinese Han Population in Kaohsiung City.
    Biomed Res Int. 2016;2016:4052846.
    Abstract    

    Abstract available

  40. RAMSEY SA, Xu T, Goodall C, Rhodes AC, et al
    Cross-Species Analysis of the Canine and Human Bladder Cancer Transcriptome and Exome.
    Genes Chromosomes Cancer. 2017 Jan 3. doi: 10.1002/gcc.22441.
    Abstract    

    Abstract available

  41. ZIGEUNER R
    Bladder cancer in 2016: News in diagnosis, treatment, and risk group assessment.
    Nat Rev Urol. 2017 Jan 4. doi: 10.1038/nrurol.2016.
    Abstract    



  42. WANG C, Wang Q, Li X, Jin Z, et al
    Lycorine induces apoptosis of bladder cancer T24 cells by inhibiting phospho-Akt and activating the intrinsic apoptotic cascade.
    Biochem Biophys Res Commun. 2016 Dec 29. pii: S0006-291X(16)32240.
    Abstract    

    Abstract available

  43. STEINBERG RL, Brooks NA, Thomas LJ, Mott SL, et al
    Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer.
    Urol Oncol. 2016 Dec 29. pii: S1078-1439(16)30404.
    Abstract    

    Abstract available

  44. LUO KW, Wei Chen, Lung WY, Wei XY, et al
    EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down-regulation of NF-kappaB and MMP-9.
    J Nutr Biochem. 2016;41:56-64.
    Abstract    

    Abstract available

  45. MOSCHINI M, Shariat SF, Luciano R, D'Andrea D, et al
    Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients.
    Clin Genitourin Cancer. 2016 Dec 14. pii: S1558-7673(16)30352.
    Abstract    

    Abstract available

  46. YANG GL, Zhang LH, Liu Q, Wang ZL, et al
    A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience.
    Urol Oncol. 2016 Dec 28. pii: S1078-1439(16)30254.
    Abstract    

    Abstract available

  47. FENG C, Ho Y, Sun C, Xia G, et al
    TFPI-2 expression is decreased in bladder cancer and is related to apoptosis.
    J BUON. 2016;21:1518-1523.
    Abstract    

    Abstract available

  48. KANG M, Jeong CW, Kwak C, Kim HH, et al
    Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor.
    Oncotarget. 2016 Dec 26. doi: 10.18632/oncotarget.14179.
    Abstract    

    Abstract available

  49. ZHEN S, Hua L, Liu YH, Sun XM, et al
    Inhibition of long non-coding RNA UCA1 by CRISPR/Cas9 attenuated malignant phenotypes of bladder cancer.
    Oncotarget. 2016 Dec 25. doi: 10.18632/oncotarget.14176.
    Abstract    

    Abstract available

  50. YU GQ, Dou ZL, Jia ZH
    [Corrigendum] 5bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2one induces apoptosis in T24 human bladder cancer cells through mitochondria-dependent signaling pathways.
    Mol Med Rep. 2016 Dec 27. doi: 10.3892/mmr.2016.6076.
    Abstract    

    Abstract available

  51. MESSING EM
    Checkpoint Inhibitors for Advanced Bladder Cancer.
    Bladder Cancer. 2016;2:473-474.
    Abstract    



  52. SHAHAIT M, Bulbul M
    Bladder Cancer Screening in Lebanese Population: There is Nothing more Unequal than the Equal Treatment of Unequal People.
    Bladder Cancer. 2016;2:467-468.
    Abstract    

    Abstract available

  53. SUI W, Matulay JT, James MB, Onyeji IC, et al
    Micropapillary Bladder Cancer: Insights from the National Cancer Database.
    Bladder Cancer. 2016;2:415-423.
    Abstract    

    Abstract available

  54. ROSE TL, Deal AM, Ladoire S, Crehange G, et al
    Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.
    Bladder Cancer. 2016;2:405-413.
    Abstract    

    Abstract available

  55. RUSSELL CM, Lebastchi AH, Borza T, Spratt DE, et al
    The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer.
    Bladder Cancer. 2016;2:381-394.
    Abstract    

    Abstract available

  56. NANDAGOPAL L, Sonpavde G
    Circulating Biomarkers in Bladder Cancer.
    Bladder Cancer. 2016;2:369-379.
    Abstract    

    Abstract available

  57. CHIANG Y, Cheng JC, Huang CY, Tsai YC, et al
    A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement.
    J Formos Med Assoc. 2016 Dec 26. pii: S0929-6646(16)30350.
    Abstract    

    Abstract available

  58. YAN X, Wu C, Chen T, Santos MM, et al
    Cathepsin S inhibition changes regulatory T-cell activity in regulating bladder cancer and immune cell proliferation and apoptosis.
    Mol Immunol. 2016;82:66-74.
    Abstract    

    Abstract available

  59. CHEN A, Liu A, Liu J, Tian S, et al
    Application of dual-energy spectral CT imaging in differential diagnosis of bladder cancer and benign prostate hyperplasia.
    Medicine (Baltimore). 2016;95:e5705.
    Abstract    

    Abstract available

  60. SIDAWAY P
    Bladder cancer: Atezolizumab: an alternative to cisplatin?
    Nat Rev Urol. 2016 Dec 29. doi: 10.1038/nrurol.2016.
    Abstract    



  61. ELLISON LF
    Differences in cancer survival in Canada by sex.
    Health Rep. 2016;27:19-27.
    Abstract    

    Abstract available

  62. POURCHET A, Fuhrmann SR, Pilones KA, Demaria S, et al
    CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy.
    EBioMedicine. 2016;5:59-67.
    Abstract    

    Abstract available

  63. VENKATESH K, Madhusudhan HR
    Anaplastic lymphoma kinase positive inflammatory myofibroblastic tumor of the urachus: A rare neoplasm in an unusual location.
    Indian J Pathol Microbiol. 2016;59:93-5.
    Abstract    

    Abstract available

  64. RALLABANDI HB, Swain M, Gowrishankar S, Sinha S, et al
    Postradiation angiosarcoma of bladder with extensive osseous metaplasia.
    Indian J Pathol Microbiol. 2016;59:78-80.
    Abstract    

    Abstract available

  65. SAKATA K, Fukuoka N, Tanabe K, Takenaka M, et al
    Anaphylactic shock due to intravesical administration of pirarubicin hydrochloride for the fifth time.
    J Clin Anesth. 2016;28:2-3.
    Abstract    

    Abstract available

  66. IWAMOTO H, Yumioka T, Yamaguchi N, Masago T, et al
    Robot-assisted radical cystectomy is a promising alternative to open surgery in the Japanese population with a high rate of octogenarians.
    Int J Clin Oncol. 2016;21:756-63.
    Abstract    

    Abstract available

  67. KIERAN K, Shnorhavorian M
    Current standards of care in bladder and prostate rhabdomyosarcoma.
    Urol Oncol. 2016;34:93-102.
    Abstract    

    Abstract available

  68. AKACHA M, Ogundimu EO
    Sensitivity analyses for partially observed recurrent event data.
    Pharm Stat. 2016;15:4-14.
    Abstract    

    Abstract available

  69. BAUMAN G
    Choosing Wisely? "It's Complicated!".
    Pract Radiat Oncol. 2016;6:71-3.
    Abstract    



  70. SHIMURA H, Ihara T, Mitsui T, Takeda M, et al
    Tuberculous Granuloma in the Scrotal Skin After Intravesical Bacillus Calmette-Guerin Therapy for Bladder Cancer: A Case Report.
    Urol Case Rep. 2017;11:4-6.
    Abstract    

    Abstract available

  71. SONG BN, Kim SK, Chu IS
    Bioinformatic identification of prognostic signature defined by copy number alteration and expression of CCNE1 in non-muscle invasive bladder cancer.
    Exp Mol Med. 2017;49:e282.
    Abstract    

    Abstract available

  72. WILBORN D, Schmidt S
    [Adjuvant chemotherapy for invasive bladder cancer (individual patient data)].
    Urologe A. 2017 Jan 11. doi: 10.1007/s00120-016-0305.
    Abstract    



  73. RINK M, Shariat SF, Soave A
    Liquid biopsies in bladder cancer-did we find the Holy Grail for biomarker analyses?
    Transl Androl Urol. 2016;5:980-983.
    Abstract    



  74. GOPALAKRISHNA A, Fantony JJ, Longo TA, Owusu R, et al
    Anticipatory Positive Urine Tests for Bladder Cancer.
    Ann Surg Oncol. 2017 Jan 10. doi: 10.1245/s10434-016-5763.
    Abstract    

    Abstract available

  75. BREYER J, Wirtz RM, Otto W, Erben P, et al
    In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
    Virchows Arch. 2017 Jan 10. doi: 10.1007/s00428-017-2064.
    Abstract    

    Abstract available

  76. POLOM W, Gruszecka A, Markuszewski M, Cytawa W, et al
    Radio-Guided Lymph Node Mapping in Bladder Cancer Using SPECT/CT and Intraoperative gamma-Probe Methods: Reply.
    Clin Nucl Med. 2017 Jan 9. doi: 10.1097/RLU.0000000000001523.
    Abstract    



  77. CRIPPA A, Larsson SC, Discacciati A, Wolk A, et al
    Red and processed meat consumption and risk of bladder cancer: a dose-response meta-analysis of epidemiological studies.
    Eur J Nutr. 2016 Dec 22. doi: 10.1007/s00394-016-1356.
    Abstract    

    Abstract available

  78. TAN M, Mu X, Liu Z, Tao L, et al
    microRNA-495 promotes bladder cancer cell growth and invasion by targeting phosphatase and tensin homolog.
    Biochem Biophys Res Commun. 2017 Jan 6. pii: S0006-291X(17)30019.
    Abstract    

    Abstract available

  79. HAMPP C, Pippins J
    Pioglitazone and bladder cancer: FDA's assessment.
    Pharmacoepidemiol Drug Saf. 2017 Jan 9. doi: 10.1002/pds.4154.
    Abstract    



  80. EL-SIDDIG AA, Albasri AM, Hussainy AS, Alhujaily AS, et al
    Urinary bladder cancer in adults: a histopathological experience from Madinah, Saudi Arabia.
    J Pak Med Assoc. 2017;67:83-86.
    Abstract    

    Abstract available

  81. MATSUMOTO K, Kikuchi E, Yanai Y, Hayakawa N, et al
    Characterizing intermediate-risk non-muscle-invasive bladder cancer: Implications for the definition of intermediate risk and treatment strategy.
    Urol Oncol. 2017 Jan 3. pii: S1078-1439(16)30402.
    Abstract    

    Abstract available

  82. KHARE SR, Aprikian A, Black P, Blais N, et al
    Quality indicators in the management of bladder cancer: A modified Delphi study.
    Urol Oncol. 2017 Jan 3. pii: S1078-1439(16)30410.
    Abstract    

    Abstract available

  83. MIZUSHIMA T, Tirador KA, Miyamoto H
    Androgen receptor activation: A prospective therapeutic target for bladder cancer?
    Expert Opin Ther Targets. 2017 Jan 9. doi: 10.1080/14728222.2017.1280468.
    Abstract    

    Abstract available

  84. VAGO R, Bettiga A, Salonia A, Ciuffreda P, et al
    Development of new inhibitors for N-acylethanolamine-hydrolyzing acid amidase as promising tool against bladder cancer.
    Bioorg Med Chem. 2016 Dec 27. pii: S0968-0896(16)31496.
    Abstract    

    Abstract available

  85. SEGOVIA C, Martinez-Fernandez M, Duenas M, Rubio C, et al
    Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer.
    Oncotarget. 2017 Jan 2. doi: 10.18632/oncotarget.14453.
    Abstract    

    Abstract available

  86. MOHAMMED AA, El-Tanni H, El-Khatib HM, Mirza AA, et al
    Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention.
    Oncol Rev. 2016;10:320.
    Abstract    

    Abstract available

  87. HUANG C, Zeng X, Jiang G, Liao X, et al
    XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cell.
    J Hematol Oncol. 2017;10:6.
    Abstract    

    Abstract available

  88. NAKAMOTO R, Nakamoto Y, Ishimori T, Togashi K, et al
    Clinical Significance of Quantitative 123I-MIBG SPECT/CT Analysis of Pheochromocytoma and Paraganglioma.
    Clin Nucl Med. 2016.
    Abstract    

    Abstract available

  89. YOSHINO T, Wake K, Yamamoto T, Onuma H, et al
    [Liposarcoma of the Spermatic Cord : A Case Report and Review of the Literature].
    Hinyokika Kiyo. 2016;62:393-7.
    Abstract    

    Abstract available

  90. DE LUCA F, Zacharakis E, Shabbir M, Maurizi A, et al
    Malignant priapism due to penile metastases: Case series and literature review.
    Arch Ital Urol Androl. 2016;88:150-2.
    Abstract    

    Abstract available

  91. STAMATIOU K, Christopoulos G, Tsavari A, Koulia K, et al
    Lymphoepithelioma-like carcinoma of the bladder: A case report.
    Arch Ital Urol Androl. 2016;88:147-9.
    Abstract    

    Abstract available

  92. UN S, Turk H, Karabicak M, Divrik RT, et al
    Is a second look necessary in multiple and/or large Ta tumors?
    Arch Ital Urol Androl. 2016;88:86-8.
    Abstract    

    Abstract available

  93. SCHEPISI G, Santoni M, Massari F, Gurioli G, et al
    Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy.
    BioDrugs. 2016;30:263-73.
    Abstract    

    Abstract available

  94. SHAW N, Marchalik D, Stamatakis L
    Incidentally discovered urachal cancer in a patient with necrotising fasciitis of the abdominal wall.
    BMJ Case Rep. 2016;2016.
    Abstract    



  95. GOMELLA PT, Frazier H
    Takotsubo stress-induced cardiomyopathy following robotic radical cystectomy.
    Can J Urol. 2016;23:8234-6.
    Abstract    

    Abstract available

  96. GREGG JR, McCormick B, Wang L, Cohen P, et al
    Short term complications from transurethral resection of bladder tumor.
    Can J Urol. 2016;23:8198-203.
    Abstract    

    Abstract available

  97. FENG Y, Kawrakow I, Olsen J, Parikh PJ, et al
    A comparative study of automatic image segmentation algorithms for target tracking in MR-IGRT.
    J Appl Clin Med Phys. 2016;17:5820.
    Abstract    

    Abstract available

  98. NISHIMOTO K, Akise Y, Miyazawa M, Kutsuki S, et al
    A Case of Severe Rectal Hemorrhage Possibly Caused by Radiation Recall after Administration of Gemcitabine.
    Keio J Med. 2016;65:16-20.
    Abstract    

    Abstract available

  99. ELSHERIF E, Elbaky TA, Elserafy F, Elkady N, et al
    beta-catenin and SKP2 proteins as predictors of grade and stage of non-muscle invasive urothelial bladder carcinoma.
    Chin Clin Oncol. 2016;5:6.
    Abstract    

    Abstract available

  100. KNUCHEL-CLARKE R, Gaisa NT
    [Preneoplastic lesions and precursors of urothelial cancer].
    Pathologe. 2016;37:33-9.
    Abstract    

    Abstract available

  101. NAYAK JG, Gore JL, Holt SK, Wright JL, et al
    Patient-centered risk stratification of disposition outcomes following radical cystectomy.
    Urol Oncol. 2016;34:235.
    Abstract    

    Abstract available

  102. AGAIMY A, Hartmann A
    [Mesenchymal tumors of the urinary bladder].
    Pathologe. 2016;37:61-70.
    Abstract    

    Abstract available

  103. THOMAS S, Hao L, Ricke WA, Li L, et al
    Biomarker discovery in mass spectrometry-based urinary proteomics.
    Proteomics Clin Appl. 2016;10:358-70.
    Abstract    

    Abstract available

  104. PULLENAYEGUM EM
    Multiple outputation for the analysis of longitudinal data subject to irregular observation.
    Stat Med. 2016;35:1800-18.
    Abstract    

    Abstract available

  105. ABDI H, Pourmalek F, Gleave ME, So AI, et al
    Balancing risk and benefit of extended pelvic lymph node dissection in patients undergoing radical cystectomy.
    World J Urol. 2016;34:41-8.
    Abstract    

    Abstract available

  106. PATEL HR, Santos PB, de Oliveira MC, Muller S, et al
    Is robotic-assisted radical cystectomy (RARC) with intracorporeal diversion becoming the new gold standard of care?
    World J Urol. 2016;34:25-32.
    Abstract    

    Abstract available

  107. KHURRAM SA, Farthing PM, Whitworth A, McKechnie AJ, et al
    High-grade urothelial carcinoma with squamous differentiation metastasizing to the tongue.
    Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121:e111-5.
    Abstract    

    Abstract available

  108. SIDDIQUI KM, Izawa JI
    Ileal conduit: standard urinary diversion for elderly patients undergoing radical cystectomy.
    World J Urol. 2016;34:19-24.
    Abstract    

    Abstract available

  109. HUGEN CM, Daneshmand S
    Orthotopic urinary diversion in the elderly.
    World J Urol. 2016;34:13-8.
    Abstract    

    Abstract available

  110. RAUP VT, Eswara JR, Geminiani J, Madison K, et al
    Gracilis muscle interposition flap repair of urinary fistulae: pelvic radiation is associated with persistent urinary incontinence and decreased quality of life.
    World J Urol. 2016;34:131-6.
    Abstract    

    Abstract available

  111. MOBLEY A, Zhang S, Bondaruk J, Wang Y, et al
    Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior.
    Sci Rep. 2017;7:40714.
    Abstract    

    Abstract available

  112. ELSEN S, Lerut E, Van Der Aa F, Van Cleynenbreugel B, et al
    Evans blue-mediated white-light detection of non-muscle-invasive bladder cancer: A preclinical feasibility and safety study using a rat bladder urothelial cell carcinoma model.
    Mol Clin Oncol. 2016;5:678-688.
    Abstract    

    Abstract available

  113. CEYLAN GG, Onalan EE, Kuloglu T, Aydog G, et al
    Potential role of melastatin-related transient receptor potential cation channel subfamily M gene expression in the pathogenesis of urinary bladder cancer.
    Oncol Lett. 2016;12:5235-5239.
    Abstract    

    Abstract available

  114. QI P, He Z, Zhang L, Fan Y, et al
    Rottlerin-induced autophagy leads to apoptosis in bladder cancer cells.
    Oncol Lett. 2016;12:4577-4583.
    Abstract    

    Abstract available

  115. GONG YQ, Peng D, Ning XH, Yang XY, et al
    UBE2T silencing suppresses proliferation and induces cell cycle arrest and apoptosis in bladder cancer cells.
    Oncol Lett. 2016;12:4485-4492.
    Abstract    

    Abstract available

  116. WANG S, Meng Q, Xie Q, Zhang M, et al
    Effect and mechanism of resveratrol on drug resistance in human bladder cancer cells.
    Mol Med Rep. 2017 Jan 12. doi: 10.3892/mmr.2017.6111.
    Abstract    

    Abstract available

  117. ITAI S, Suga Y, Hara Y, Izumi K, et al
    Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study.
    J Pharm Health Care Sci. 2017;3:3.
    Abstract    

    Abstract available

  118. STONE L
    Bladder cancer: Genetic urinary biomarker panel is promising.
    Nat Rev Urol. 2017 Jan 17. doi: 10.1038/nrurol.2017.
    Abstract    



  119. LV D, Wu H, Xing R, Shu F, et al
    HnRNP-L mediates bladder cancer progression by inhibiting apoptotic signaling and enhancing MAPK signaling pathways.
    Oncotarget. 2017 Jan 11. doi: 10.18632/oncotarget.14600.
    Abstract    

    Abstract available

  120. LLORETA J, Font-Tello A, Juanpere N, Frances A, et al
    FOXO1 downregulation is associated with worse outcome in bladder cancer and adds significant prognostic information to p53 overexpression.
    Hum Pathol. 2017 Jan 10. pii: S0046-8177(17)30011.
    Abstract    

    Abstract available

  121. MOSCHINI M, Dell'Oglio P, Luciano' R, Gandaglia G, et al
    Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy.
    Urol Oncol. 2017 Jan 10. pii: S1078-1439(16)30413.
    Abstract    

    Abstract available

  122. RIPPY SB, Gardner HL, Nguyen SM, Warry EE, et al
    A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma.
    BMC Vet Res. 2016;12:257.
    Abstract    

    Abstract available

  123. SHAH BK, Rajwani T, Jha S, Fortna RR, et al
    Chronic lymphocytic leukemia presenting with hematuria.
    Acta Oncol. 2017;56:113-115.
    Abstract    



  124. ANZIVINO E, Zingaropoli MA, Iannetta M, Pietropaolo VA, et al
    Archetype and Rearranged Non-coding Control Regions in Urothelial Bladder Carcinoma of Immunocompetent Individuals.
    Cancer Genomics Proteomics. 2016;13:499-509.
    Abstract    

    Abstract available

  125. ABDEL-GAWAD M, Elsobky E, Shalaby MM, Abd-Elhameed M, et al
    Quantitative Evaluation of Heavy Metals and Trace Elements in the Urinary Bladder: Comparison Between Cancerous, Adjacent Non-cancerous and Normal Cadaveric Tissue.
    Biol Trace Elem Res. 2016;174:280-286.
    Abstract    

    Abstract available

  126. ROPERTO S, Russo V, Leonardi L, Martano M, et al
    Bovine Papillomavirus Type 13 Expression in the Urothelial Bladder Tumours of Cattle.
    Transbound Emerg Dis. 2016;63:628-634.
    Abstract    

    Abstract available

  127. ZHU L, Zhou L, Wang L, Li Z, et al
    A20 SNP rs77191406 may be related to secondary cancer for rheumatoid arthritis and systemic lupus erythematosus patients.
    Asia Pac J Clin Oncol. 2016;12:409-414.
    Abstract    

    Abstract available

  128. FUJII T, Asano A, Shimada K, Tatsumi Y, et al
    Evaluation of RNA and DNA extraction from liquid-based cytology specimens.
    Diagn Cytopathol. 2016;44:833-40.
    Abstract    

    Abstract available

  129. LIN DM, Barkan GA, Chatt G, Park JW, et al
    Vaginal fine-needle aspiration: A useful alternative to biopsy.
    Diagn Cytopathol. 2016;44:665-9.
    Abstract    

    Abstract available

  130. CSOMA E, Bidiga L, Mehes G, Gergely L, et al
    No Evidence of Human Polyomavirus 9, WU and KI DNA in Kidney and Urinary Bladder Tumour Tissue Samples.
    Pathobiology. 2016;83:252-7.
    Abstract    

    Abstract available

  131. ISHIKAWA R, Kadota K, Hayashi T, Motoyama M, et al
    Cytopathological features of villous adenoma of the urinary bladder in urine: A rare case report.
    Diagn Cytopathol. 2016;44:632-5.
    Abstract    

    Abstract available

  132. MITRA S, Chatterjee D, Gupta K, Dass Radotra B, et al
    Urine cytology of urothelial carcinoma with villoglandular differentiation.
    Diagn Cytopathol. 2016;44:653-6.
    Abstract    



  133. ABUSANAD OZ, Floyd MS Jr, Khattak AQ
    Acute Urinary Retention in a Female Following Bladder Tumor Resection Due To a Stone in a Urethral Diverticulum.
    Urol J. 2016;13:2656.
    Abstract    



  134. LIANG J, Li H, Gao L, Yin L, et al
    Bladder Paraganglioma: Clinicopathology and Magnetic Resonance Imaging Study of Five Patients.
    Urol J. 2016;13:2605-11.
    Abstract    

    Abstract available

  135. THORNQVIST S, Hysing LB, Tuomikoski L, Vestergaard A, et al
    Adaptive radiotherapy strategies for pelvic tumors - a systematic review of clinical implementations.
    Acta Oncol. 2016;55:943-58.
    Abstract    

    Abstract available

  136. RUAN HJ, Huang AH, Cheng S, Fu GX, et al
    [Clinicopathologic features of solitary fibrous tumor in urogenital system].
    Zhonghua Bing Li Xue Za Zhi. 2016;45:248-51.
    Abstract    

    Abstract available

  137. GLASS R, Cocker R, Rosen L, Coutsouvelis C, et al
    The impact of subdividing the "atypical" category for urinary cytology on patient management.
    Diagn Cytopathol. 2016;44:477-82.
    Abstract    

    Abstract available

  138. YANG H, Liu ZM, Lei YH, Qin Y, et al
    [Analysis of life-threatening complications during perioperative period in patients undergoing radical cystectomy with orthotopic neobladder].
    Zhonghua Zhong Liu Za Zhi. 2016;38:236-9.
    Abstract    

    Abstract available

  139. SEO GH, Kim JH, Ku JH
    Clinical Practice Pattern of Immediate Intravesical Chemotherapy following Transurethral Resection of a Bladder Tumor in Korea: National Health Insurance Database Study.
    Sci Rep. 2016;6:22716.
    Abstract    

    Abstract available

  140. TONE K, Kojima K, Hoshiai K, Kumagai N, et al
    An ancillary method in urine cytology: Nucleolar/nuclear volume ratio for discrimination between benign and malignant urothelial cells.
    Diagn Cytopathol. 2016;44:483-91.
    Abstract    

    Abstract available

  141. ALME AK, Karir BS, Faltas BM, Drake CG, et al
    Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.
    Urol Oncol. 2016;34:171-81.
    Abstract    

    Abstract available

  142. GAI JW, Qin W, Liu M, Wang HF, et al
    Expression profile of hydrogen sulfide and its synthases correlates with tumor stage and grade in urothelial cell carcinoma of bladder.
    Urol Oncol. 2016;34:166.
    Abstract    

    Abstract available

  143. KIM HC, Hong WP, Lim YJ, Park HP, et al
    The effect of sevoflurane versus desflurane on postoperative catheter-related bladder discomfort in patients undergoing transurethral excision of a bladder tumour: a randomized controlled trial.
    Can J Anaesth. 2016;63:596-602.
    Abstract    

    Abstract available

  144. SAIDI S, Popov Z, Janevska V, Panov S, et al
    Overexpression of UHRF1 gene correlates with the major clinicopathological parameters in urinary bladder cancer.
    Int Braz J Urol. 2017;43.
    Abstract    

    Abstract available

  145. KATA SG, Zreik A, Ahmad S, Chlosta P, et al
    Concurrent bladder cancer in patients undergoing photodynamic diagnostic ureterorenoscopy: how many lesions do we miss under white light cystoscopy?
    Cent European J Urol. 2016;69:334-340.
    Abstract    

    Abstract available

  146. PIOTROWICZ S, Poletajew S, Czarniecki SW, Kowalski F, et al
    Extent of lymphadenectomy in patients with bladder cancer undergoing radical cystectomy - a multi-institutional analysis.
    Cent European J Urol. 2016;69:323-326.
    Abstract    

    Abstract available

  147. KRISHNA SR, Konety BR
    Current Concepts in the Management of Muscle Invasive Bladder Cancer.
    Indian J Surg Oncol. 2017;8:74-81.
    Abstract    

    Abstract available

  148. PRACK MC CORMICK B, Belgorosky D, Langle Y, Balarino N, et al
    Bacillus Calmette-Guerin improves local and systemic response to radiotherapy in invasive bladder cancer.
    Nitric Oxide. 2017 Jan 23. pii: S1089-8603(16)30143.
    Abstract    

    Abstract available

  149. ARRUDA RP, Mariano MB, Pereira CF, Lima GC, et al
    Laparoscopic Cystoprostatectomy for Bladder Cancer in a Male patient combined with open ileal conduit urinary diversion.
    Int Braz J Urol. 2017;43:169-170.
    Abstract    



  150. CIMEN HI, Halis F, Saglam HS, Gokce A, et al
    Can neutrophil to lymphocyte ratio predict lamina propria invasion in patients with non muscle invasive bladder cancer?
    Int Braz J Urol. 2017;43:67-72.
    Abstract    

    Abstract available

  151. SO A
    Bladder cancer, ESMO 2016.
    Can Urol Assoc J. 2016;10.
    Abstract    



  152. WANG H, Li Q, Niu X, Wang G, et al
    miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling.
    Oncol Lett. 2017;13:435-440.
    Abstract    

    Abstract available

  153. MATSUO T, Miyata Y, Mitsunari K, Yasuda T, et al
    Pathological significance and prognostic implications of heme oxygenase 1 expression in non-muscle-invasive bladder cancer: Correlation with cell proliferation, angiogenesis, lymphangiogenesis and expression of VEGFs and COX-2.
    Oncol Lett. 2017;13:275-280.
    Abstract    

    Abstract available

  154. MUKHERJEE N, Cardenas E, Bedolla R, Ghosh R, et al
    SETD6 regulates NF-kappaB signaling in urothelial cell survival: Implications for bladder cancer.
    Oncotarget. 2017 Jan 19. doi: 10.18632/oncotarget.14750.
    Abstract    

    Abstract available

  155. RUSSO V, Inglese C, Avallone L, Roperto F, et al
    Sigma 2 receptor expression levels in blood and bladder from healthy and bladder cancer cattle.
    Vet Comp Oncol. 2017 Jan 25. doi: 10.1111/vco.12295.
    Abstract    

    Abstract available

  156. WAN YP, Xi M, He HC, Wan S, et al
    Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer.
    Oncol Res Treat. 2017;40.
    Abstract    



  157. ROBINSON AG, Wei X, Vera-Badillo FE, Mackillop WJ, et al
    Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population.
    Clin Genitourin Cancer. 2016 Dec 29. pii: S1558-7673(16)30371.
    Abstract    

    Abstract available

  158. SHEPHARD RJ
    Physical activity in the prevention and management of bladder cancer.
    J Sports Med Phys Fitness. 2017 Jan 23. doi: 10.23736/S0022-4707.17.06830.
    Abstract    

    Abstract available

  159. ZHANG Z, Zeng S, Zhao J, Lu X, et al
    A Pilot Study of Vela Laser for En Bloc Resection of Papillary Bladder Cancer.
    Clin Genitourin Cancer. 2016 Jun 23. pii: S1558-7673(16)30150.
    Abstract    

    Abstract available

  160. JIANG Z, Zhang Y, Cao R, Li L, et al
    MiR-5195-3p inhibits proliferation and invasion of human bladder cancer cells by directly targeting oncogene KLF5.
    Oncol Res. 2017 Jan 20. doi: 10.3727/096504016X14831120463349.
    Abstract    

    Abstract available

  161. LU J, Zheng X, Li F, Yu Y, et al
    Tunneling nanotubes promote intercellular mitochondria transfer followed by increased invasiveness in bladder cancer cells.
    Oncotarget. 2017 Jan 17. doi: 10.18632/oncotarget.14695.
    Abstract    

    Abstract available

  162. TAKAI T, Yoshikawa Y, Inamoto T, Minami K, et al
    A Novel Combination RNAi toward Warburg Effect by Replacement with miR-145 and Silencing of PTBP1 Induces Apoptotic Cell Death in Bladder Cancer Cells.
    Int J Mol Sci. 2017;18.
    Abstract    

    Abstract available

  163. FANTONY JJ, Longo TA, Gopalakrishna A, Owusu R, et al
    Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.
    Cancer Biomark. 2017 Jan 13. doi: 10.3233/CBM-160261.
    Abstract    

    Abstract available

  164. CHA KH, Hadjiiski LM, Samala RK, Chan HP, et al
    Bladder Cancer Segmentation in CT for Treatment Response Assessment: Application of Deep-Learning Convolution Neural Network-A Pilot Study.
    Tomography. 2016;2:421-429.
    Abstract    

    Abstract available

  165. TAKEUCHI H, Tokuyama N, Kuroda I, Aoyagi T, et al
    Annular rectal constriction caused by infiltrating bladder cancer: A case report.
    Mol Clin Oncol. 2016;5:842-844.
    Abstract    

    Abstract available

  166. LI R, Choi W, Ferguson Rd JE, Metcalfe MJ, et al
    New discoveries in the molecular landscape of bladder cancer.
    F1000Res. 2016;5:2875.
    Abstract    

    Abstract available

  167. SHENG Z, Liu Y, Qin C, Liu Z, et al
    Involvement of cancer-derived IgG in the proliferation, migration and invasion of bladder cancer cells.
    Oncol Lett. 2016;12:5113-5121.
    Abstract    

    Abstract available

  168. FALTAS BM, Tagawa ST
    Immune-checkpoint blockade in cisplatin-ineligible patients with urothelial cancer.
    Lancet. 2017;389:6-7.
    Abstract    



  169. LIU J, Li D, Cao L, Wang Z, et al
    Elevated preoperative plasma fibrinogen level is an independent predictor of malignancy and advanced stage disease in patients with bladder urothelial tumors.
    Int J Surg. 2016;36.
    Abstract    

    Abstract available

  170. DURING VA, Sole GM, Jha AK, Anderson JA, et al
    Prediction of histological stage based on cytoscopic appearances of newly diagnosed bladder tumours.
    Ann R Coll Surg Engl. 2016;98:547-551.
    Abstract    

    Abstract available

  171. SHARMA A, Sharma S, Patnaik N, Pradhan D, et al
    Cytomorphologic and Immunophenotypic Profile of a Cohort of Small Cell Carcinoma of the Urinary Bladder.
    Acta Cytol. 2016;60:475-480.
    Abstract    

    Abstract available

  172. MOROZUMI K, Namiki S, Nakamura Y
    [Inflammatory Myofibroblastic Tumor of the Bladder : A Case Report].
    Hinyokika Kiyo. 2016;62:427-30.
    Abstract    

    Abstract available

  173. GAYE AM, Doh K, Thiam I, Bentefouet L, et al
    [Schistosomiasis and cancer: A fortuitous association or relationships cause and effect].
    Bull Cancer. 2016;103:806-7.
    Abstract    



  174. WASHIO M, Mori M, Mikami K, Miki T, et al
    Risk Factors for Upper and Lower Urinary Tract Cancer Death in a Japanese Population: Findings from the Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC Study).
    Asian Pac J Cancer Prev. 2016;17:3545-9.
    Abstract    

    Abstract available

  175. XIN Z, Zhao C, Huang T, Zhang Z, et al
    Intestinal metaplasia of the bladder in 89 patients: a study with emphasis on long-term outcome.
    BMC Urol. 2016;16:24.
    Abstract    

    Abstract available

  176. ALRASHIDY M, Atef A, Baky TA
    Immunohistochemical Differentiation between Urothelial Papillomas and Papillary Neoplasms of Low Malignant Potential of the Urinary Bladder.
    Asian Pac J Cancer Prev. 2016;17:1769-72.
    Abstract    

    Abstract available

  177. ALBERTI C
    Whyever bladder tissue engineering clinical applications still remain unusual even though many intriguing technological advances have been reached?
    G Chir. 2016;37:6-12.
    Abstract    

    Abstract available

  178. ALEXANDER RE, Wang L, Lopez-Beltran A, Emerson RE, et al
    Human papillomavirus (HPV)-induced neoplasia in the urinary bladder: a missing link?
    Histol Histopathol. 2016;31:595-600.
    Abstract    

    Abstract available

  179. HAHN AW, Giri S, Pathak R, Bhatt VR, et al
    Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract.
    Anticancer Res. 2016;36:4051-5.
    Abstract    

    Abstract available

  180. HUSSEIN AA, Hinata N, Dibaj S, May PR, et al
    Development, Validation and Clinical Application of Pelvic Lymphadenectomy Assessment and Completion Evaluation (PLACE): Intraoperative Assessment of Lymph Node Dissection after Robot-Assisted Radical Cystectomy for Bladder Cancer.
    BJU Int. 2016 Dec 17. doi: 10.1111/bju.13748.
    Abstract    

    Abstract available

  181. WOLDU SL, Bagrodia A, Lotan Y
    Guideline of Guidelines - Non-Muscle Invasive Bladder Cancer.
    BJU Int. 2017 Jan 6. doi: 10.1111/bju.13760.
    Abstract    

    Abstract available

  182. CHOUDHURY A, West CM, Porta N, Hall E, et al
    The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).
    Br J Cancer. 2017 Jan 26. doi: 10.1038/bjc.2017.
    Abstract    

    Abstract available

  183. PACKIAM VT, Johnson SC, Steinberg GD
    Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guerin.
    Cancer. 2017;123:390-400.
    Abstract    

    Abstract available

  184. OWCZAREK TB, Kobayashi T, Ramirez R, Rong L, et al
    ARF confers a context-dependent response to chemotherapy in muscle invasive bladder cancer.
    Cancer Res. 2017 Jan 12. pii: canres.2621.2016.
    Abstract    

    Abstract available

  185. GUIN S, Ru Y, Agarwal N, Lew CR, et al
    Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis.
    Clin Cancer Res. 2016;22:1274-83.
    Abstract    

    Abstract available

  186. HERRMANN TR, Wolters M, Kramer MW
    Transurethral en bloc resection of nonmuscle invasive bladder cancer: trend or hype.
    Curr Opin Urol. 2016 Dec 28. doi: 10.1097/MOU.0000000000000377.
    Abstract    

    Abstract available

  187. SELTZ LM, Herrell SD
    Applications of spectroscopy in diagnosis, staging, and treatment of urologic malignancies.
    Curr Opin Urol. 2016;26:259-63.
    Abstract    

    Abstract available

  188. KHAN MS, Gan C, Ahmed K, Ismail AF, et al
    A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
    Eur Urol. 2016;69:613-21.
    Abstract    

    Abstract available

  189. SELINSKI S, Gerullis H, Otto T, Roth E, et al
    Ultra-slow N-Acetyltransferase 2 Is Associated with Recurrence-free Time in Bladder Cancer Patients.
    Eur Urol. 2016 Dec 28. pii: S0302-2838(16)30904.
    Abstract    



  190. GIACALONE NJ, Shipley WU, Clayman RH, Niemierko A, et al
    Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Eur Urol. 2017 Jan 9. pii: S0302-2838(16)30924.
    Abstract    

    Abstract available

  191. DE VERE WHITE R
    Re: Management of Nonmuscle Invasive Bladder Cancer: A Comprehensive Analysis of Guidelines from the Unites States, Europe, and Asia.
    Eur Urol. 2017 Jan 7. pii: S0302-2838(16)30921.
    Abstract    



  192. CHRISTENSEN E, Birkenkamp-Demtroder K, Nordentoft I, Hoyer S, et al
    Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Eur Urol. 2017 Jan 6. pii: S0302-2838(16)30920.
    Abstract    

    Abstract available

  193. ROTH B
    Re: Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures.
    Eur Urol. 2017 Jan 13. pii: S0302-2838(17)30012.
    Abstract    



  194. HADKHALE K, Martinsen JI, Weiderpass E, Kjaerheim K, et al
    Occupational exposure to solvents and bladder cancer: A population-based case control study in Nordic countries.
    Int J Cancer. 2016 Dec 29. doi: 10.1002/ijc.30593.
    Abstract    

    Abstract available

  195. ALEVIZOPOULOS A, Tyritzis S, Leotsakos I, Anastasopoulou I, et al
    Role of coagulation factors in urological malignancy: A prospective, controlled study on prostate, renal and bladder cancer.
    Int J Urol. 2016 Dec 22. doi: 10.1111/iju.13271.
    Abstract    

    Abstract available

  196. DAL MORO F, Zattoni F
    Lighting from the urethral cystoscope side: A novel technique to safely manage bowel division during intracorporeal robotic urinary diversion.
    Int J Urol. 2016;23:344-5.
    Abstract    



  197. JINZAKI M, Kikuchi E, Akita H, Sugiura H, et al
    Role of computed tomography urography in the clinical evaluation of upper tract urothelial carcinoma.
    Int J Urol. 2016;23:284-98.
    Abstract    

    Abstract available

  198. MATSUMURA N, Nakamura Y, Kohjimoto Y, Nishizawa S, et al
    Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.
    Int J Urol. 2017 Jan 9. doi: 10.1111/iju.13274.
    Abstract    

    Abstract available

  199. ALIMI Q, Verhoest G, Kammerer-Jacquet SF, Mathieu R, et al
    Response to Re: Role of routine computed tomography scan in the oncological follow up of patients treated by radical cystectomy for bladder cancer.
    Int J Urol. 2017 Jan 13. doi: 10.1111/iju.13290.
    Abstract    



  200. OTTO W, Breyer J, Herdegen S, Eder F, et al
    WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
    Int Urol Nephrol. 2016 Dec 29. doi: 10.1007/s11255-016-1491.
    Abstract    

    Abstract available

  201. JO JK, Jeong SJ, Hong SK, Byun SS, et al
    The impact of preoperative anemia on oncologic outcome in patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
    Int Urol Nephrol. 2016;48:489-94.
    Abstract    

    Abstract available

  202. ROBINSON R, Tait CD, Somov P, Lau MW, et al
    Estimated glomerular filtration rate is unreliable in detecting renal function loss during follow-up after cystectomy and urinary diversion.
    Int Urol Nephrol. 2016;48:511-5.
    Abstract    

    Abstract available

  203. TONYALI S, Yazici S
    Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies?
    Int Urol Nephrol. 2016;48:671-80.
    Abstract    

    Abstract available

  204. POWLES T, Huddart RA, Elliott T, Sarker SJ, et al
    Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
    J Clin Oncol. 2017;35:48-55.
    Abstract    

    Abstract available

  205. CHOU R, Selph S, Buckley DI, Fu R, et al
    Intravesical Therapy for the Treatment of Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    J Urol. 2016 Dec 24. pii: S0022-5347(16)32091-2. doi: 10.1016/j.juro.2016.
    Abstract    

    Abstract available

  206. PATEL S, Cookson MS
    Radical Cystectomy-The Waiting is the Hardest Part...or is it?
    J Urol. 2016;195.
    Abstract    



  207. HUSSEIN AA, Hashmi Z, Dibaj S, Altartir T, et al
    Reoperations following Robot-Assisted Radical Cystectomy: A Decade of Experience.
    J Urol. 2016;195:1368-76.
    Abstract    

    Abstract available

  208. BEUKERS W, van der Keur KA, Kandimalla R, Vergouwe Y, et al
    FGFR3, TERT and OTX1 as urinary biomarker combination for surveillance of bladder cancer patients in a large prospective multicenter study.
    J Urol. 2016 Dec 31. pii: S0022-5347(16)32099-7. doi: 10.1016/j.juro.2016.
    Abstract    

    Abstract available

  209. SHENOY SP, Marla PK, Sharma P, Batchu CK, et al
    Re: Sequential bacillus Calmette-Guerin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes: C. Gan, S. Amery, K. Chatterton, M. S. Khan, K. Thomas and T
    J Urol. 2016 Dec 28. pii: S0022-5347(16)31927-9. doi: 10.1016/j.juro.2016.
    Abstract    



  210. YU G, Jia Z, Dou Z
    miR-24-3p regulates bladder cancer cell proliferation, migration, invasion and autophagy by targeting DEDD.
    Oncol Rep. 2016 Dec 16. doi: 10.3892/or.2016.5326.
    Abstract    

    Abstract available

  211. DENG QF, Sun X, Liang ZF, Zhang ZQ, et al
    Cigarette smoke extract induces the proliferation of normal human urothelial cells through the NF-kappaB pathway.
    Oncol Rep. 2016;35:2665-72.
    Abstract    

    Abstract available

  212. CHEN JF, Yu BX, Yu R, Ma L, et al
    Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis.
    Oncol Rep. 2017 Jan 5. doi: 10.3892/or.2017.5356.
    Abstract    

    Abstract available

  213. BREYER J, Otto W, Wirtz RM, Wullich B, et al
    ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.
    Urol Int. 2016.
    Abstract    

    Abstract available

  214. SOORIAKUMARAN P, Chiocchia V, Dutton S, Pai A, et al
    Predictive Factors for Time to Progression after Hyperthermic Mitomycin C Treatment for High-Risk Non-Muscle Invasive Urothelial Carcinoma of the Bladder: An Observational Cohort Study of 97 Patients.
    Urol Int. 2016;96:83-90.
    Abstract    

    Abstract available

  215. SERRETTA V, Scalici Gesolfo C, Alonge V, Cicero G, et al
    Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?
    Urol Int. 2016;96:20-4.
    Abstract    

    Abstract available

  216. MARTINI T, Aziz A, Roghmann F, Rink M, et al
    Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy--A Prospective Multicenter Study.
    Urol Int. 2016;96:57-64.
    Abstract    

    Abstract available

  217. MILLER K, Morant R, Stenzl A, Zuna I, et al
    A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transi
    Urol Int. 2016;96:5-13.
    Abstract    

    Abstract available

  218. TANAKA H, Yoshida S, Komai Y, Sakai Y, et al
    Clinical Value of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Upper Tract Urothelial Carcinoma: Impact on Detection of Metastases and Patient Management.
    Urol Int. 2016;96:65-72.
    Abstract    

    Abstract available

  219. SHINTANI T, Kusuhara Y, Daizumoto K, Dondoo TO, et al
    The Involvement of HGF-MET-MMP1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells.
    Urology. 2016 Dec 21. pii: S0090-4295(16)30945.
    Abstract    

    Abstract available

  220. CHAPPIDI MR, Kates M, Brant A, Baras AS, et al
    Assessing Cancer Progression and Stable Disease after Neoadjuvant Chemotherapy for Organ-Confined Muscle-Invasive Bladder Cancer.
    Urology. 2017 Jan 16. pii: S0090-4295(17)30031.
    Abstract    

    Abstract available

  221. BAI Y, Wang X, Yang Y, Tang Y, et al
    Parity and bladder cancer risk: a dose-response meta-analysis.
    BMC Cancer. 2017;17:31.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;